



## **uMed Announces Strategic Partnership with WellSky® to Expand Patient Access to National Clinical Research Registries**

*New initiative enables patients to participate in national research registries from home, with no disruption to care*

**London – December 18, 2025** – uMed, a real-world evidence and patient cohort company, today announced a strategic partnership with WellSky to significantly expand patient access to national clinical research registries across the U.S. The collaboration enables patients receiving home-based care to participate in longitudinal research studies from their own homes, with no disruption to routine care. By combining the WellSky network of more than 10,000 home-based care organisations with uMed’s automated registry platform, the collaboration creates a scalable model for collecting high-quality real-world clinical information from patients. This is particularly significant for underserved, rural, and ageing populations—who want to participate in clinical research, with no disruption to their routine or care.

“uMed’s mission is to make research more accessible and representative,” said Matt Wilson, MD, founder and CEO of uMed. “By partnering with WellSky, we can significantly expand the scale of our national registries, reaching patients where they already receive care and accelerating recruitment without adding burden to providers or patients.”

A key focus of the collaboration is improving recruitment and retention in disease-specific registries, including AccessCMD, uMed’s national cardiometabolic disease cohort.

“Recruiting large, representative cardiometabolic cohorts has historically been a major challenge for research,” said Associate Professor Mark Toshner, University of Cambridge, Principal Investigator of AccessCMD. “By embedding research into home-based care pathways, we can generate more robust and generalisable real-world data that better reflects the populations most affected by cardiometabolic disease.”

“Access to participate in clinical research has historically been limited for many patients, particularly those not connected to major academic medical centres,” said Bill Miller, chairman and CEO of WellSky. “By integrating WellSky’s expansive provider network with uMed’s turnkey registry infrastructure, we are establishing a new framework for inclusive, patient-centred research that meets individuals where they are.”

The initiative will launch with cardiometabolic and Parkinson’s disease cohorts in January 2026, with plans to expand into additional therapeutic areas over time.

### **About uMed**

uMed is a real-world evidence and patient cohort company that makes clinical research participation easier and more representative. Through its ACCESS Cohorts platform, uMed builds national, longitudinal registries by linking electronic health records with scalable patient-reported outcomes, generating high-quality real-world data across various conditions. uMed partners with health systems, life-science companies, and care providers to accelerate research, improve understanding of patient journeys, and support evidence generation for regulators, payers, and clinical decision-making. Originally founded in the U.K. and headquartered in Boston. <https://umed.io/>

### **uMed Media Contact**

Serena Macleod  
Phone: +44 7787 537370  
Email: [serena.macleod@umed.io](mailto:serena.macleod@umed.io)

### **WellSky Media Contact**

Emma Neal  
Phone: 617.401.3131  
Email: [emma.neal@allisonworldwide.com](mailto:emma.neal@allisonworldwide.com)

### **About WellSky®**

WellSky is one of America's largest and most innovative healthcare technology companies leading the movement for intelligent, coordinated care. Our proven software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today's value-based care environment, WellSky helps providers, payers, health systems, and community organisations scale processes, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, home health and hospice franchises, post-acute providers, government agencies, and human services organisations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients' needs and innovates relentlessly to build healthy, thriving communities. For more information, visit [wellsky.com](http://wellsky.com).

###